Literature DB >> 27894703

Over surgery in breast cancer.

Fiona MacNeill1, Andreas Karakatsanis2.   

Abstract

Breast surgery remains the original and most effective 'targeted' therapy: excision of early cancer is curative and for more advanced disease surgery improves local disease control. However in well intentioned pursuit of cure and local disease control, some cancers are over-treated resulting in major physical and emotional morbidity. Less breast surgery is safe, as evidenced by steady reductions in mortality and local recurrence; earlier diagnosis and widespread use of systemic therapies and radiotherapy have allowed more conservative surgery. As tumour biology dictates cancer outcomes not surgery extent, surgery can safely be 'minimum required' rather than 'more is better' with the focus on removal of disease rather than healthy tissue. Surgeons can reduce the burden of surgery further but it is important that less surgery is not over-compensated by more radical or unnecessary systemic therapies and/or radiotherapy with their own toxicities and morbidity. We all need to be alert to the potential drivers of over treatment and over surgery such as failure to work within a multidisciplinary team, failure to design a multimodality treatment plan at diagnosis or overuse of novel assessment technologies of uncertain clinical utility. Pursuit of wide margins and the removal of the contra-lateral healthy breast for marginal risk-reduction gains are also to be discouraged as is routine local/regional surgery in stage 4 disease. The surgeon has a pivotal role in minimizing breast surgery to what is required to achieve the best oncological, functional and aesthetic outcomes.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Breast cancer surgery; De-escalation of breast cancer surgery; Less is more; Overdoing surgery; Overtreatment; Personalised surgery

Mesh:

Year:  2016        PMID: 27894703     DOI: 10.1016/j.breast.2016.10.023

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  5 in total

Review 1.  Update of the American Society of Breast Surgeons Toolbox to address the lumpectomy reoperation epidemic.

Authors:  Maureen P McEvoy; Jeffrey Landercasper; Himani R Naik; Sheldon Feldman
Journal:  Gland Surg       Date:  2018-12

Review 2.  The sick lobe hypothesis, field cancerisation and the new era of precision breast surgery.

Authors:  Mona P Tan; Tibor Tot
Journal:  Gland Surg       Date:  2018-12

3.  Towards the use of diffuse reflectance spectroscopy for real-time in vivo detection of breast cancer during surgery.

Authors:  Lisanne L de Boer; Torre M Bydlon; Frederieke van Duijnhoven; Marie-Jeanne T F D Vranken Peeters; Claudette E Loo; Gonneke A O Winter-Warnars; Joyce Sanders; Henricus J C M Sterenborg; Benno H W Hendriks; Theo J M Ruers
Journal:  J Transl Med       Date:  2018-12-19       Impact factor: 5.531

4.  Attenuated measles vaccine strain have potent oncolytic activity against Iraqi patient derived breast cancer cell line.

Authors:  Sulaiman A Abdullah; Ahmed Majeed Al-Shammari; Safaa A Lateef
Journal:  Saudi J Biol Sci       Date:  2019-12-19       Impact factor: 4.219

Review 5.  Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors.

Authors:  Chao Li; Xujun Li
Journal:  Onco Targets Ther       Date:  2021-05-03       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.